Published online Aug 26, 2015. doi: 10.4252/wjsc.v7.i7.1010
Peer-review started: October 14, 2014
First decision: January 8, 2015
Revised: June 8, 2015
Accepted: June 18, 2015
Article in press: June 19, 2015
Published online: August 26, 2015
Core tip: To achieve clinical applications, stem cell-based therapy must shift from lab experimentation to clinical grade stem cells. We present here the development of advanced therapy medicinal products (ATMP) by the banking of dental pulp stem cells (DPSCs) for allogenic use. The dental pulp represents an efficient tool for industrial applications due to its accessibility after wisdom teeth extraction for orthodontic purpose. DPSC therapeutic batches can be produced in good manufacturing practice condition after human leukocyte antigen typing and stored in allogenic biobanks. We propose some clinical applications, for which there is no efficient therapeutics so far, but that DPSCs-based ATMP could potentially treat.